Fosun Henlius Enters into Licensing Agreement with Eisai for HANSIZHUANG® (Serplulimab) in Oncology Indications

Shanghai Henlius Biotech, Inc.(02696) announced that on February 5, 2026, the company entered into a licensing agreement with Eisai Co., Ltd. (Eisai), under which the company agreed to grant Eisai a license to develop, manufacture, and commercialize 汉斯状® (Sulrilimab Injection) in Japan and within the field. The licensed product is intended for the treatment of oncology indications.

Eisai will pay the Company: (a) an upfront payment of 75 million US dollars, to be paid upon the execution of the license agreement; (b) regulatory milestone payments totaling up to 80.01 million US dollars, based on the achievement of various regulatory milestones for the licensed product within the region; (c) commercial sales milestone payments totaling up to approximately 233 million US dollars, based on the level of annual net sales of the licensed product within the region; and (d) royalties in the double-digit percentage of the annual net sales of the licensed product within the region.

It is reported that Hansizhuang® (Serplulimab Injection), an innovative anti-PD-1 monoclonal antibody independently developed by the company, has been approved for marketing in China (excluding Hong Kong, Macao, and Taiwan regions, hereinafter the same) for the following indications: first-line treatment in combination with chemotherapy for squamous non-small cell lung cancer (sq-NSCLC), extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC), and non-squamous non-small cell lung cancer (nsq-NSCLC). Meanwhile, Hansizhuang® has also been approved for marketing in the European Union, the United Kingdom, Indonesia, Cambodia, Thailand, Malaysia, Singapore, India, and other countries/regions. It has also been granted orphan drug designation by the pharmaceutical regulatory authorities in the United States, the European Union, Switzerland, and South Korea. In addition, the company is steadily advancing multiple clinical trials of Hansizhuang® and related combination therapies globally, covering a wide range of indications including lung cancer, esophageal cancer, head and neck squamous cell carcinoma, colorectal cancer, and gastric cancer. In December 2025, the drug registration application for Hansizhuang® in combination with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer was accepted by the National Medical Products Administration (NMPA) and has been included in the priority review and approval process.

This commercialization collaboration with Eisai regarding the licensed products in the region will help further expand the overseas market for the company’s products, enhance the accessibility and recognition of the company’s products in the international market, thereby creating conditions for the continuous increase of the company’s revenue.